Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral: Vanier Canada Graduate Scholarships

University of Toronto

$100,000.00

Identification of novel ependymoma tumour suppressor genes by genome-wide DNA methylation profiling.

EF 2009-10

Résumé
Ependymoma is the third most common pediatric brain tumour. To this date all efforts to develop ependymoma chemotherapy treatments have failed. This is in large part due to our poor understanding of the molecular basis of this disease. Our research has identified numerous genes deregulated in ependymoma tumourigenesis which may serve as the first rationale targets of molecular therapy. We envision that the results of these experiments will allow us to better understand the genetic mechanisms contributing to ependymooma, and ultimately improve survival of patients suffering from this disease.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
197238
Name
Mack Stephen
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Identification of novel ependymoma tumour suppressor genes by genome-wide DNA methylation profiling.
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Brain Tumor; Dna Methylation; Epigenetics; Expression Profiling; Gap Junction Signaling; Genetics; Methylated Dna Immunoprecipitation; Microarray; Next Generation Sequencing; Paediatric
Abstract
Ependymoma is the third most common pediatric brain tumour. To this date all efforts to develop ependymoma chemotherapy treatments have failed. This is in large part due to our poor understanding of the molecular basis of this disease. Our research has identified numerous genes deregulated in ependymoma tumourigenesis which may serve as the first rationale targets of molecular therapy. We envision that the results of these experiments will allow us to better understand the genetic mechanisms contributing to ependymooma, and ultimately improve survival of patients suffering from this disease.
Competitiondate
200911
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Mack, Stephen
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $100,000~ $0~